{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:37:40Z","timestamp":1794339460369,"version":"4.9.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105396","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:06:01Z","timestamp":1779951961000},"page":"105396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-8006","authenticated-orcid":false,"given":"Antonio","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariapia","family":"Marafioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Madonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105396_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0327588","article-title":"The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer","volume":"20","author":"Abdollahi","year":"2025","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105396_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0327588","article-title":"The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer","volume":"20","author":"Abdollahi","year":"2025","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105396_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s43018-023-00575-2","article-title":"Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS","volume":"4","author":"Adachi","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jtho.2025.01.006","article-title":"A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)","volume":"20","author":"Akamatsu","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib5","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/2159-8290.CD-24-0421","article-title":"Mechanisms of response and tolerance to active RAS inhibition in KRAS -mutant non\u2013small cell lung cancer","volume":"14","author":"Araujo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib6","doi-asserted-by":"crossref","first-page":"S1005","DOI":"10.1016\/j.annonc.2022.07.1116","article-title":"989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)","volume":"33","author":"Awad","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib7","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS G12C Inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105396_bib8","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2767-9764.CRC-23-0482","article-title":"Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers","volume":"4","author":"Bagnyukova","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105396_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2767-9764.CRC-23-0482","article-title":"Synergy of EGFR and AURKA inhibitors in KRAS-mutated non-small cell lung cancers","volume":"4","author":"Bagnyukova","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105396_bib10","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/j.annonc.2025.08.2145","article-title":"1514O First-in-human phase I study of TCR-T therapy targeting KRAS G12V in metastatic solid tumors","volume":"36","author":"Bai","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105396_bib12","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1038\/s41467-020-17022-w","article-title":"A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS","volume":"11","author":"Bery","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105396_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.787585","article-title":"Resistance to KRASG12C Inhibitors in non-small cell lung cancer","volume":"11","author":"Blaquier","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/28548","article-title":"The structural basis of the activation of Ras by Sos","volume":"394","author":"Boriack-Sjodin","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105396_bib15","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: Critical Elements in the Control of Small G Proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105396_bib16","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2021.39.15_suppl.3005","article-title":"Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors","volume":"39","author":"Brana","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib17","unstructured":"BridgeBio Oncology Therapeutics Press Release [WWW Document], 2026. URL \u3008https:\/\/investors.bbotx.com\/news-releases\/news-release-details\/bbot-granted-us-fda-fast-track-designation-bbo-11818-treatment\u3009 (accessed 5.15.26)."},{"key":"10.1016\/j.critrevonc.2026.105396_bib18","article-title":"Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC","author":"Burns","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105396_bib20","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/JCO.2023.41.16_suppl.9007","article-title":"KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C -mutated solid tumors including non-small cell lung cancer (NSCLC)","volume":"41","author":"Cassier","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib21","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41591-025-03688-6","article-title":"D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial","volume":"31","author":"Cho","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105396_bib22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105396_bib23","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1021\/acs.jmedchem.4c02313","article-title":"Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105396_bib24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105396_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108683","article-title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial","volume":"207","author":"Dingemans","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib26","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jtho.2022.07.022","article-title":"OA03.03 Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors","volume":"17","author":"Falchook","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib27","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ccell.2025.07.006","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers","volume":"43","author":"Feng","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105396_bib28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jmb.2010.03.046","article-title":"What Makes Ras an Efficient Molecular Switch: A Computational, Biophysical, and Structural Study of Ras-GDP Interactions with Mutants of Raf","volume":"399","author":"Filchtinski","year":"2010","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104250","article-title":"Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236","volume":"30","author":"Filis","year":"2025","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.critrevonc.2026.105396_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","article-title":"Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer","volume":"139","author":"Gerber","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.96992.3","article-title":"Inhibition of ULK1\/2 and KRASG12C controls tumor growth in preclinical models of lung cancer","volume":"13","author":"Ghazi","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.critrevonc.2026.105396_bib32","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.96992.3","article-title":"Inhibition of ULK1\/2 and KRASG12C controls tumor growth in preclinical models of lung cancer","volume":"13","author":"Ghazi","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.critrevonc.2026.105396_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","article-title":"Combination Therapies with CDK4\/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer","volume":"83","author":"Goodwin","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105396_bib34","article-title":"KRAS mutation as a prognostic factor and predictive factor in advanced\/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis","volume":"24","author":"Goulding","year":"2020","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105396_bib35","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1073\/pnas.1617709114","article-title":"Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma","volume":"114","author":"Gouw","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105396_bib36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1470-2045(25)00764-8","article-title":"Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b\/2 trial","volume":"27","author":"Gregorc","year":"2026","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib37","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib38","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2024.42.16_suppl.3007","article-title":"Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors","volume":"42","author":"Heist","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib39","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14656566.2025.2536352","article-title":"Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)","volume":"26","author":"Herrmann","year":"2025","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.critrevonc.2026.105396_bib40","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS\u2013SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105396_bib41","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105396_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2026.105396_bib43","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105396_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in Non\u2013Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105396_bib45","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1556-0864(23)00262-9","article-title":"8MO Adagrasib (MRTX849) in patients with advanced\/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency","volume":"18","author":"J\u00e4nne","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib46","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2025.43.16_suppl.8500","article-title":"First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced\/metastatic KRAS G12C -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study","volume":"43","author":"J\u00e4nne","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib47","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib48","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.jtho.2025.09.109","article-title":"MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01","volume":"20","author":"Johnson","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib49","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BCJ20220234","article-title":"Dynamic regulation of RAS and RAS signaling","volume":"480","author":"Kolch","year":"2023","journal-title":"Biochem. J."},{"key":"10.1016\/j.critrevonc.2026.105396_bib51","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jtho.2025.09.057","article-title":"OA08.04 Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC","volume":"20","author":"Lee","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib52","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2023.07.006","article-title":"Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives","volume":"18","author":"Lee","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib53","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2024.42.16_suppl.8512","article-title":"Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib54","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2022.40.16_suppl.102","article-title":"Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non\u2013small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib55","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.critrevonc.2026.105396_bib56","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","article-title":"D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results","volume":"18","author":"Li","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"issue":"1979","key":"10.1016\/j.critrevonc.2026.105396_bib58","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105396_bib59","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","article-title":"Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C","volume":"15","author":"Maciag","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","article-title":"Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management","volume":"27","author":"Manousaridis","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib62","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41388-021-02156-y","article-title":"Neurofibromin and suppression of tumorigenesis: beyond the GAP","volume":"41","author":"Mo","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105396_bib63","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216692","article-title":"AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells","volume":"587","author":"Morimoto","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105396_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216692","article-title":"AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells","volume":"587","author":"Morimoto","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105396_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102309","article-title":"KRAS Inhibitors\u2013 yes but what next? Direct targeting of KRAS\u2013 vaccines, adoptive T cell therapy and beyond","volume":"101","author":"Nagasaka","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105396_bib67","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jtho.2023.09.151","article-title":"MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors","volume":"18","author":"Negrao","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib68","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.jtho.2025.09.055","article-title":"OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01","volume":"20","author":"Negrao","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib69","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib70","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1016\/j.jtho.2024.09.636","article-title":"P3.12E.04 Long-Term Outcomes with Sotorasib in KRAS G12c-Mutated Advanced NSCLC from the Global Expanded Access Program (EAP) Study-436","volume":"19","author":"Novello","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib71","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105396_bib72","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human Phase I\/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1979","key":"10.1016\/j.critrevonc.2026.105396_bib73","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: Know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105396_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107444","article-title":"Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program","volume":"187","author":"Passiglia","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib75","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1538-7445.AM2023-1142","article-title":"Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C","volume":"83","author":"Patel","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105396_bib76","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","article-title":"Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State","volume":"6","author":"Patricelli","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib77","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ccell.2024.05.020","article-title":"Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue","volume":"42","author":"Perurena","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105396_bib78","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/2159-8290.CD-18-1220","article-title":"Tissue-Specific Oncogenic Activity of KRASA146T","volume":"9","author":"Poulin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib79","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in Cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105396_bib80","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1556-0864(25)00201-1","article-title":"6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)","volume":"20","author":"Punekar","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib81","doi-asserted-by":"crossref","first-page":"ND11","DOI":"10.1158\/1538-7445.AM2022-ND11","article-title":"Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers","volume":"82","author":"Purkey","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105396_bib82","doi-asserted-by":"crossref","first-page":"P05-01","DOI":"10.1158\/1535-7163.TARG-21-P05-01","article-title":"Abstract P05-01: A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors","volume":"20","author":"Ramalingam","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105396_bib83","unstructured":"Revolution Medicines Press Release [WWW Document], 2025. URL \u3008https:\/\/ir.revmed.com\/node\/11636\/\u3009 (accessed 5.15.26)."},{"key":"10.1016\/j.critrevonc.2026.105396_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1530541","article-title":"Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions","volume":"15","author":"Ruan","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib85","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105396_bib86","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO-25-00040","article-title":"Single-Agent Divarasib in Patients With KRAS G12C \u2013Positive Non\u2013Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study","volume":"43","author":"Sacher","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib87","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1200\/JCO.2025.43.16_suppl.8605","article-title":"MK-1084 for KRAS G12C-mutated (mut) metastatic non\u2013small-cell lung cancer (mNSCLC): Results from KANDLELIT-001","volume":"43","author":"Sacher","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib88","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1200\/JCO.2025.43.16_suppl.8605","article-title":"MK-1084 for KRAS G12C-mutated (mut) metastatic non\u2013small-cell lung cancer (mNSCLC): Results from KANDLELIT-001","volume":"43","author":"Sacher","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35783","article-title":"Advances in the treatment of KRAS G12C mutant non\u2013small cell lung cancer","volume":"131","author":"Shaverdashvili","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib90","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","article-title":"Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial","volume":"31","author":"Shi","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105396_bib91","doi-asserted-by":"crossref","first-page":"12826","DOI":"10.1073\/pnas.1921964117","article-title":"High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D","volume":"117","author":"Sim","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105396_bib92","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105396_bib93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","article-title":"A Gene Expression Signature Associated with \u201cK-Ras Addiction\u201d Reveals Regulators of EMT and Tumor Cell Survival","volume":"15","author":"Singh","year":"2009","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105396_bib94","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105396_bib95","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae356","article-title":"Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer","volume":"30","author":"Skoulidis","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105396_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq4274","article-title":"SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition","volume":"10","author":"Song","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105396_bib97","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1200\/JCO.2025.43.16_suppl.8629","article-title":"Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib\/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC)","volume":"43","author":"Song","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116153","article-title":"Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1\/2 study","volume":"232","author":"Song","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib99","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-25-1280","article-title":"Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multiple Oncogenic Mutants","volume":"16","author":"Stahlhut","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113911","article-title":"Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany","volume":"201","author":"Stratmann","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib101","doi-asserted-by":"crossref","first-page":"S2053","DOI":"10.1016\/j.annonc.2025.10.689","article-title":"977MO Safety and efficacy of elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C NSCLC","volume":"36","author":"Tan","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib102","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS\u2013MAPK Reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105396_bib103","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1158\/1078-0432.CCR-15-2603","article-title":"Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer","volume":"22","author":"Tang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105396_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218194","article-title":"SRC at the crossroads of KRAS inhibitor resistance: Mechanisms and therapeutic opportunities","volume":"639","author":"Tian","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105396_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218194","article-title":"SRC at the crossroads of KRAS inhibitor resistance: Mechanisms and therapeutic opportunities","volume":"639","author":"Tian","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105396_bib106","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","article-title":"Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer","volume":"42","author":"Tong","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105396_bib107","doi-asserted-by":"crossref","first-page":"S808","DOI":"10.1016\/j.annonc.2024.08.1318","article-title":"1261P Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib108","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105396_bib109","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","article-title":"Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer","volume":"629","author":"Wasko","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105396_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115301","article-title":"Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study","volume":"219","author":"Wislez","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114088","article-title":"Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC","volume":"230","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105396_bib112","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178535","article-title":"YAP\/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5\/mTOR axis","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2026.105396_bib113","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178535","article-title":"YAP\/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5\/mTOR axis","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2026.105396_bib114","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.trecan.2021.04.003","article-title":"Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy","volume":"7","author":"Yang","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105396_bib115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105396_bib116","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2025.43.16_suppl.8520","article-title":"Sosimerasib monotherapy in patients with previously treated KRAS G12C\u2013mutated non-small cell lung cancer: Primary results of a phase 2 study","volume":"43","author":"Zhong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib117","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jtho.2024.08.005","article-title":"Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study","volume":"19","author":"Zhou","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105396_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114337","article-title":"Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study","volume":"212","author":"Zhou","year":"2024","journal-title":"Eur. J. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:55:01Z","timestamp":1787108101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":118,"alternative-id":["S1040842826002830"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105396","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105396"}}